Crohn's Disease News and Research

Latest Crohn's Disease News and Research

DNMT3a plays a key role in regulating HSC responses to infections

Humans are born with tens of thousands of hematopoietic stem cells (HSCs) that collectively ensure lifelong production of blood and immune cells that protect us from infections.

26 Mar 2021

New method could drive down the production cost of antibodies

Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn's disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.

22 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

Whole-genome study of IBD in African Americans reveals a different genetic risk landscape

In African Americans, the genetic risk landscape for inflammatory bowel disease (IBD) is very different from that of people with European ancestry, according to results of the first whole-genome study of IBD in African Americans.

20 Feb 2021

Study reveals genetic signature of colibactin implicated in the development colorectal cancers

Escherichia coli bacteria are constitutive members of the human gut microbiota. However, some strains produce a genotoxin called colibactin, which is implicated in the development of colorectal cancer.

18 Feb 2021

Nanotherapy shows potential for treating severe Crohn's disease

Scientists from the Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago demonstrated that a nanotherapy reduces intestinal inflammation and shrinks lesions in a rodent model of severe Crohn's disease.

17 Feb 2021

Research shows how chemicals in the tumor microenvironment enable cancer to evade attack

A paper published today in Nature shows how chemicals in the areas surrounding tumors--known as the tumor microenvironment--subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.

15 Feb 2021

Study could help develop drugs for pregnancy maintenance, treat autoimmune diseases

A team of scientists from Immanuel Kant Baltic Federal University with their colleagues from the Institute of Ecology and Genetics of Microorganisms of the Ural Branch of the Russian Academy of Sciences (Perm) studied the effect of trophoblastic β1-glycoprotein in the blood of pregnant women on pro-inflammatory immune cells.

10 Feb 2021

Inherited genetic variation may affect the response to cancer immunotherapy

For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small minority of patients, perhaps 15 percent across different types of cancer.

10 Feb 2021

Novel method instructs immune cells to help repair damaged tissues in the intestine

A method that instructs immune system cells to help repair damaged tissues in the intestine has been developed by researchers at KU Leuven and Seoul National University.

8 Feb 2021

Discovery of ‘Achilles heel’ in gut bacteria may lead to targeted therapies for Crohn’s disease

The discovery of an "Achilles heel" in a type of gut bacteria that causes intestinal inflammation in patients with Crohn's disease may lead to more targeted therapies for the difficult to treat disease, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

6 Feb 2021

New diagnostic imaging tool measures naturally occurring enzymes in the gastrointestinal tract

A healthy person has a general balance of good and bad bacteria. But that balance is thrown off when someone gets sick.

5 Feb 2021

Crafoord Laureate uncovered a new group of rare autoinflammatory diseases

Dan Kastner, USA, has described an entirely new group of rare autoinflammatory diseases. His discoveries have brought new knowledge and led to the development of effective treatments.

1 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

New partnership to develop test for predicting disease course in pediatric Crohn's patients

The Crohn's & Colitis Foundation, the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), has entered into a partnership with LifeArc, an independent medical research charity that advances translation of early science into health care treatments or diagnostics, to potentially develop the first clinical lab test to predict disease course in pediatric patients with Crohn's disease and response to treatment.

25 Jan 2021

CoQ10 supplement could be a valuable complementary therapeutic option for various diseases

A study led by scientists from the University of Granada (UGR) has found that a supplement of Coenzyme Q10 (CoQ10), an essential molecule for life that is synthesized in the cells of our organs and tissues and is also acquired through diet, could constitute a valuable complementary therapeutic option in the treatment of certain mitochondrial diseases, colon cancer, thyroid carcinoma, and Crohn’s disease.

18 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Polygenic risk scores from multi-population data could improve IBD predictions

Using genetic data from nearly 30,000 people, Mount Sinai researchers have built risk scores from a combination of datasets representing distinct ancestral populations that improve prediction of risk for inflammatory bowel diseases (IBD) including Crohn's disease and ulcerative colitis. The study was published in Gastroenterology on December 24.

24 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

DNMT3a plays a key role in regulating HSC responses to infections

New method could drive down the production cost of antibodies

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

Whole-genome study of IBD in African Americans reveals a different genetic risk landscape

Study reveals genetic signature of colibactin implicated in the development colorectal cancers

Nanotherapy shows potential for treating severe Crohn's disease

Research shows how chemicals in the tumor microenvironment enable cancer to evade attack

Study could help develop drugs for pregnancy maintenance, treat autoimmune diseases

Inherited genetic variation may affect the response to cancer immunotherapy

Novel method instructs immune cells to help repair damaged tissues in the intestine

Discovery of ‘Achilles heel’ in gut bacteria may lead to targeted therapies for Crohn’s disease

New diagnostic imaging tool measures naturally occurring enzymes in the gastrointestinal tract

Crafoord Laureate uncovered a new group of rare autoinflammatory diseases

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

New partnership to develop test for predicting disease course in pediatric Crohn's patients

CoQ10 supplement could be a valuable complementary therapeutic option for various diseases

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Polygenic risk scores from multi-population data could improve IBD predictions

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in